Niagen Bioscience (NAGE) is a strong buy due to its patented NAD+ boosting molecule, significant sales growth, expanding distribution channels, and a defensible IP moat, making the current price dip an attractive entry point for long-term investors.
Source Post
Is Niagen Bioscience Inc NAGE A Good Time To Buy Now? NAGE Stock Analysis
Mar 15, 2026
The podcast discusses Niagen Bioscience (NAGE), a company focused on healthy aging through its patented molecule, Nicotinamide Riboside (NR), which boosts NAD+ levels. Despite initial skepticism about the wellness industry, the analysis highlights Niagen's strong intellectual property, significant year-over-year sales growth (33%), and strategic expansion into e-commerce and HSA/FSA channels. The valuation is considered reasonable for a growth-stage bioscience firm, and the stock's recent price dip is viewed as a potential entry point for long-term investors. The overall sentiment is bullish, with an "8 out of 10" score, emphasizing the company's strong fundamentals, competitive moat, and favorable market trends.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
NAGEbuy opened Mar 15, 2026
-31.17%